hANGPTL3(5)
Nomenclature
C57BL/6JSmo-Angptl3tm3(hANGPTL3)Smoc
Cat. NO.
NM-HU-230047
Strain State
Repository Live
Gene Summary
Gene Symbol
Angptl3
Model Description
Validation Data

Fig.1 Detection of ANGPTL3 expression in liver of HO hANGPTL3(5) mice by RT-PCR. (male, 8wks)
Wild type: only one band at 155 bp with primers F1/R1(mAngptl3);
Homozygous: only one band at 155 bp with primers F2/R2(hANGPTL3).
Abbr. M, DNA marker; HO, homozygous; WT, wild type.

Fig.2 Detection of human ANGPTL3 expression in serum by ELISA (n=3).
Abbr. HO, homozygous; WT, wild type; N.D. not detected.

Table.1 Blood biochemical test of WT mice and hANGPTL3(5) knockin mice.
Values are expressed as mean±SEM.
Abbr. HO, homozygous; WT, wild type.
● In vivo efficacy of ANGPTL3 RNAi (ARO-ANG3) in hANGPTL3(5) mice.

Fig.3 Detection of human ANGPTL3 levels in serum of hANGPTL3(5) knock-in mice after ARO-ANG3 treatment. Compared to the vehicle group, human ANGPTL3 expression was significantly decreased in the ARO-ANG3 treatment groups in a dose-dependent manner. hANGPTL3(5) mice (male, 15 weeks old) were randomized into four equal groups according to body weight, blood chemistry parameters, and baseline ANGPTL3 levels (n = 5/group). Mice were administered saline or ARO-ANG3 at doses of 0.3, 1, or 3 mg/kg. ARO-ANG3 is a nucleic acid drug targeting human ANGPTL3, synthesized according to the relevant patents. Serum human ANGPTL3 levels were assessed 6 days after dosing. (Mean ± SEM. t-test, *p < 0.05, **p < 0.01, ***p < 0.001).
Abbr. HO, homozygous.

Fig.4 Serum lipid profiles of hANGPTL3(5) mice after ARO-ANG3 treatment. Compared to vehicle, TG, T-CHO, and HDL-C were significantly decreased in the ARO-ANG3 treatment group. hANGPTL3(5) mice (male, 15 weeks old) were randomized into four equal groups according to body weight, blood chemistry parameters, and baseline ANGPTL3 levels (n = 5/group). Mice were administered saline or ARO-ANG3 at doses of 0.3, 1, or 3 mg/kg. ARO-ANG3 is a nucleic acid drug targeting human ANGPTL3, synthesized according to the relevant patents. Blood biochemistry parameters were assessed 6 days after dosing. (Mean ± SEM. t-test, *p < 0.05, **p < 0.01, ***p < 0.001).
Abbr. HO, homozygous.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn moreMilestones
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
Learn more